Last updated on May 2017

A Biomarker-Driven Master Protocol for Previously Treated Squamous Cell Lung Cancer (SWOG S1400)


Brief description of study

A Biomarker-Driven Master Protocol for Previously Treated Squamous Cell Lung Cancer (SWOG S1400)

Detailed Study Description

Squamous NSCLC (any stage); at least one platinum-based line of chemo; Tx on sub-studies based on central lab biomarker testing. The Lung-MAP study is a large clinical trial that is testing new treatments for patients who have advanced-stage squamous cell lung cancer. There are many different changes to a person’s cancer genes that can cause squamous cells to grow out of control. Researchers have developed new drugs that might “target” these genetic changes better and with fewer side effects. The Lung-MAP study hopes to learn if the drugs that target the genetic changes in the cancer cells will slow or stop the squamous cell lung cancer from growing.

Clinical Study Identifier: TX149724

Contact Investigators or Research Sites near you

Start Over

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.